Developer docs
API playgroundTry for free, no card

Search company profiles

Raisonance

Full company profile

uuid0002k6c

Namestring
Raisonance
Legal namestring
RAIsonance, Inc.
Websiteurl
raisonance.ai
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDenver, United States
HQ citystring
Denver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI cough analysis, respiratory disease screening, clinical decision support, biometric health monitoring, respiratory diagnostics software
Industry3 codes
PRIMARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code2 codes
  • Medical Laboratories621511
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
AI Clinical Decision Support Software
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Enterprise / Institutional Software Licensing (AudibleHealth AI)
TypeSubscription Recurring
Description

Clinical decision support screening software licensed to healthcare providers, government health programs, military, and pharmacy chains for respiratory disease screening (TB, COVID-19, Pneumonia, Influenza). Pricing model not publicly disclosed; contracts and pricing are quote-based.

raisonance.ai
2Subscription / SaaS (FCV Sentinel)
TypeSubscription Recurring
Description

FCV Sentinel biometric early-warning service for individuals, large employers, colleges/universities, airline and cruise passengers. Includes interactive aggregate dashboards for organizational customers; recurring SaaS revenue model inferred from continuous monitoring use case.

raisonance.ai
3Government / Defense Contracts (BARDA)
TypeManaged Services
Description

AudibleHealth AI respiratory screening software was developed in part under contract from BARDA (Biomedical Advanced Research and Development Authority) to detect COVID-19 and Influenza. Revenue generated via federal contracting channel.

raisonance.ai
4Exempt Securities Offering / Equity Financing
TypeLicensing Royalties
Description

Form D exempt securities offering of $6.5 million total, with $2.5 million sold at time of filing (SEC, 2022-08-11). Capital-raising activity supporting company growth.

sec.gov
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure, Supply Chain
Pricing details2 tiers
1Quote-based enterprise contract for AudibleHealth AI screening
ModelOther
Notes

Pricing not publicly disclosed; positioned as fast, portable, inexpensive, non-invasive screening relative to traditional lab diagnostics; intended for healthcare providers and community health programs.

raisonance.ai
2Quote-based subscription for FCV Sentinel with enterprise dashboards
ModelSubscription
Notes

Pricing not publicly disclosed; offered with interactive dashboards for group tracking and readiness; targets individuals, employers, universities, airlines, cruise lines.

raisonance.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1AudibleHealth AI
Description

Clinical decision support software designed to detect disease signatures in a cough sound; screens for respiratory diseases such as Tuberculosis, COVID-19, Pneumonia, and Influenza via a smartphone-based cough recording.

raisonance.ai
+2 more records
Core offering1 text field

Raisonance develops AI/ML-based cough analysis software that screens for respiratory diseases (Tuberculosis, COVID-19, Pneumonia, Influenza) and provides biometric early-warning monitoring via a smartphone-based platform. Its core product AudibleHealth AI is a clinical decision support tool that analyzes a 10-second cough recording against 5,000+ data points, delivering results in approximately 30 seconds on Microsoft Azure cloud infrastructure, with FDA Emergency Use Authorization and ISO 13485 certification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • ~30 second result turnaround from 10-second cough recording
+5 more records
Product overview1 text field

Raisonance operates a single underlying AI technology platform — Forced Cough Vocalization (FCV) Signature Analysis — which powers two core commercial product lines: AudibleHealth AI, a clinical decision support product that screens for specific respiratory diseases (currently Tuberculosis and COVID-19, with Pneumonia and Influenza in final testing) using a 10-second smartphone cough recording analyzed in Microsoft's Azure cloud in ~30 seconds; and FCV Sentinel, a biometric early-warning monitoring product that tracks an individual's FCV scores against their unique baseline and surfaces notable changes as an FCV Impact Score. Together with an industry-specific FCV Smoker Detection module for insurance underwriting, the two commercial lines share the same patented AI/ML pipeline that analyzes over 5,000 data points per cough, live across multiple countries and supported by a BARDA contract for COVID-19 and Influenza development.

Product and service3 records
1AudibleHealth AI
CategoryCore product / Clinical decision support software
Description

Clinical decision support software that screens for respiratory diseases by analyzing a cough sound collected via a smartphone app. Users cough for ~10 seconds and receive results in ~30 seconds, with no swabs, waste, or waiting. Currently screens for Tuberculosis and COVID-19, with Pneumonia and Influenza in final testing and 15+ additional test types on the roadmap. Developed in part under a BARDA contract for COVID-19 and Influenza.

2FCV Sentinel
CategoryCore product / Biometric monitoring software
Description

Threat-agnostic early warning system based on Raisonance's proprietary Forced Cough Vocalization (FCV) analysis. Tracks FCV scores over time to flag notable changes in an individual's respiratory profile; delivers an FCV Impact Score (0-99) and aggregate dashboards for organizations. Does not diagnose conditions or distinguish between pathogens and chemical agents.

3FCV Smoker Detection
CategoryIndustry-specific screening module
Description

Solution built on the AudibleHealth AI platform for the insurance underwriting industry that identifies whether an individual is a cigarette smoker based on cough analysis.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
1Microsoft Azure
Strategic tierFlagshipTypeTechnology or Integration
Description

Cloud production infrastructure partner. RAIsonance solutions run on Microsoft Azure; cough recordings are pushed to the Azure cloud and results returned in approximately 30 seconds. The scalable Azure infrastructure can currently process over 20,000 screenings per second. Also an alumnus/affiliate of Microsoft for Startups (logo displayed on website).

raisonance.ai
Strategic tierFlagshipTypeGTM or Marketing Partner
Description

U.S. federal contracting partner. AudibleHealth AI respiratory screening software was developed in part with a BARDA contract to detect COVID-19 and Influenza.

3THE 5Ps, LLC (Major General Elder Granger)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Strategic Advisory Lead for Government and Military Medical Programs. General Granger (retired U.S. Army Major General) appointed April 2026 to lead RAIsonance's global strategic efforts with government and military programs, drawing on prior leadership of TRICARE (overseeing 9M+ beneficiaries) and the 44th Medical Command.

raisonance.ai
4Christine Hrudka (Pharmacy Industry Strategic Advisory)
Strategic tierFlagshipTypeGTM or Marketing Partner
Description

Strategic Advisory Lead for the Pharmacy Industry appointed January 2026. Former Chair of Canadian Pharmacists Association; 20+ years operating Shoppers Drug Mart locations; will lead pharmacy programs across Canada, the United Kingdom, Australia and the US.

raisonance.ai
5DRIVe (Division of Research, Innovation, and Ventures)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as partner on Our Partners page linking to drive.hhs.gov/digitalmcm.html, indicating engagement with HHS DRIVe (often a BARDA-adjacent innovation accelerator).

raisonance.ai
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Featured partner on RAIsonance's Our Partners page linking to sotertechnologies.com. Likely regional distribution or technology collaboration partner.

7Biotech Latam
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Featured partner on Our Partners page linking to biometric.biotechlatam.solutions, suggesting Latin American distribution or biometric services collaboration.

raisonance.ai
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Featured partner on Our Partners page linking to healthexpress365.com, likely a healthcare distribution or screening services partner.

9Well Before
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Featured partner on Our Partners page linking to wellbefore.com, likely a consumer/retail health products distribution partner.

raisonance.ai
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

11Aequus
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

raisonance.ai
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

13Dawapay
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

raisonance.ai
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

18Salessquad
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

raisonance.ai
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australian digital health company (acquired by Pfizer in 2022) that developed machine-learning analysis of cough sounds to diagnose respiratory diseases including pneumonia, asthma, and COPD. Closest direct peer to RAIsonance's AudibleHealth AI cough-based clinical decision support product.

TypeDirect peer
Description

AI cough-monitoring platform that analyzes cough frequency and patterns via smartphone microphones for respiratory disease tracking. Closely comparable to RAIsonance's FCV Sentinel use case of continuous cough-based monitoring, with a more research/consumer-research orientation.

TypeDirect peer
Description

Voice biomarker platform using vocal audio analysis (including cough) for health monitoring and mental/physical condition detection. Directly comparable to RAIsonance's audio-based biomarker approach, though Sonde has emphasized mental health and cognitive conditions rather than respiratory screening.

TypeDirect peer
Description

Digital stethoscope plus AI platform that analyzes lung and heart sounds for respiratory and cardiac conditions, including FDA-cleared AI for detecting pulmonary conditions. Comparable AI-audio respiratory diagnostics competitor, though Eko uses a dedicated stethoscope rather than a generic smartphone.

TypeDirect peer
Description

Digital respiratory health platform combining remote spirometry, symptom tracking, and AI for asthma/COPD management. Comparable to RAIsonance's respiratory disease screening and monitoring product set, with overlapping enterprise payer/provider business models.

6Kintsugi
TypeEmerging player
Description

Voice biomarker startup using short voice clips to detect depression and other mental/physical health conditions. Comparable as an emerging audio-biomarker health AI company with a different clinical focus (mental health) than RAIsonance's respiratory focus.

TypeOthers
Description

Maker of GeneXpert molecular diagnostic systems (the confirmatory TB/COVID testing RAIsonance flags patients for). Indirectly tied to RAIsonance as the downstream confirmatory testing modality; not a competitor but the established incumbent whose installed base RAIsonance's screening complements rather than displaces.

8Babylon Health
TypeBroad incumbent
Description

AI-powered digital health and triage company offering symptom assessment and virtual care across multiple disease areas. Broad incumbent in AI health screening; competes for the same enterprise/payer budgets that fund AI-driven respiratory screening pilots.

9Biofourmis
TypeBroad incumbent
Description

AI-based remote patient monitoring and digital therapeutics platform focused on chronic conditions including respiratory. Comparable as a broader AI health monitoring incumbent, especially relevant to RAIsonance's FCV Sentinel enterprise monitoring use cases.

TypeOthers
Description

Healthcare data and analytics platform serving hospitals and health systems. Indirect adjacency: Health Catalyst sits in the hospital IT/analytics stack where RAIsonance's screening outputs would integrate, rather than directly competing in respiratory diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Raisonance

AI Clinical Decision Support Softwareraisonance.ai

Raisonance firmographics

Firmographics
Name
Raisonance
Legal name
RAIsonance, Inc.
Website
https://raisonance.ai
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Raisonance industry classification

Industry
Product category
AI Clinical Decision Support Software
NAICS
Medical Laboratories (621511), Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • AI cough analysis
  • Respiratory disease screening
  • Clinical decision support
  • Biometric health monitoring
  • Respiratory diagnostics software

Where Raisonance is headquartered

Location

Headquarters

HQ city
Denver
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Raisonance business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure, Supply Chain

Revenue model

  1. Enterprise / Institutional Software Licensing (AudibleHealth AI): Clinical decision support screening software licensed to healthcare providers, government health programs, military, and pharmacy chains for respiratory disease screening (TB, COVID-19, Pneumonia, Influenza). Pricing model not publicly disclosed; contracts and pricing are quote-based.
  2. Subscription / SaaS (FCV Sentinel): FCV Sentinel biometric early-warning service for individuals, large employers, colleges/universities, airline and cruise passengers. Includes interactive aggregate dashboards for organizational customers; recurring SaaS revenue model inferred from continuous monitoring use case.
  3. Government / Defense Contracts (BARDA): AudibleHealth AI respiratory screening software was developed in part under contract from BARDA (Biomedical Advanced Research and Development Authority) to detect COVID-19 and Influenza. Revenue generated via federal contracting channel.
  4. Exempt Securities Offering / Equity Financing: Form D exempt securities offering of $6.5 million total, with $2.5 million sold at time of filing (SEC, 2022-08-11). Capital-raising activity supporting company growth.

Pricing tiers

ModelBillingPrice
Other—Quote-based enterprise contract for AudibleHealth AI screening
Subscription—Quote-based subscription for FCV Sentinel with enterprise dashboards

Go-to-market motion4 records

Distribution channels5 records

Marketing channels9 records

Raisonance product offering

Product offering

Core offering

Raisonance develops AI/ML-based cough analysis software that screens for respiratory diseases (Tuberculosis, COVID-19, Pneumonia, Influenza) and provides biometric early-warning monitoring via a smartphone-based platform. Its core product AudibleHealth AI is a clinical decision support tool that analyzes a 10-second cough recording against 5,000+ data points, delivering results in approximately 30 seconds on Microsoft Azure cloud infrastructure, with FDA Emergency Use Authorization and ISO 13485 certification.

Product overview

Raisonance operates a single underlying AI technology platform — Forced Cough Vocalization (FCV) Signature Analysis — which powers two core commercial product lines: AudibleHealth AI, a clinical decision support product that screens for specific respiratory diseases (currently Tuberculosis and COVID-19, with Pneumonia and Influenza in final testing) using a 10-second smartphone cough recording analyzed in Microsoft's Azure cloud in ~30 seconds; and FCV Sentinel, a biometric early-warning monitoring product that tracks an individual's FCV scores against their unique baseline and surfaces notable changes as an FCV Impact Score. Together with an industry-specific FCV Smoker Detection module for insurance underwriting, the two commercial lines share the same patented AI/ML pipeline that analyzes over 5,000 data points per cough, live across multiple countries and supported by a BARDA contract for COVID-19 and Influenza development.

Differentiator

Problem solved

Functional benefit

Brands

  • AudibleHealth AI: Clinical decision support software designed to detect disease signatures in a cough sound; screens for respiratory diseases such as Tuberculosis, COVID-19, Pneumonia, and Influenza via a smartphone-based cough recording.
  • FCV Sentinel
  • FCV Wellness

Products and services

  • AudibleHealth AI Clinical decision support software that screens for respiratory diseases by analyzing a cough sound collected via a smartphone app. Users cough for ~10 seconds and receive results in ~30 seconds, with no swabs, waste, or waiting. Currently screens for Tuberculosis and COVID-19, with Pneumonia and Influenza in final testing and 15+ additional test types on the roadmap. Developed in part under a BARDA contract for COVID-19 and Influenza.
  • FCV Sentinel Threat-agnostic early warning system based on Raisonance's proprietary Forced Cough Vocalization (FCV) analysis. Tracks FCV scores over time to flag notable changes in an individual's respiratory profile; delivers an FCV Impact Score (0-99) and aggregate dashboards for organizations. Does not diagnose conditions or distinguish between pathogens and chemical agents.
  • FCV Smoker Detection Solution built on the AudibleHealth AI platform for the insurance underwriting industry that identifies whether an individual is a cigarette smoker based on cough analysis.

Quantifiable outcome

  • ~30 second result turnaround from 10-second cough recording
  • +5 more outcomes

Companies that use Raisonance

Customer profile

Segments7 records

Ideal customer profiles5 records

Raisonance technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Raisonance partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered flagship, core and minor.

  • Microsoft AzureflagshipTechnology or IntegrationCloud production infrastructure partner. RAIsonance solutions run on Microsoft Azure; cough recordings are pushed to the Azure cloud and results returned in approximately 30 seconds. The scalable Azure infrastructure can currently process over 20,000 screenings per second. Also an alumnus/affiliate of Microsoft for Startups (logo displayed on website).
  • BARDA (Biomedical Advanced Research and Development Authority)flagshipGTM or Marketing PartnerU.S. federal contracting partner. AudibleHealth AI respiratory screening software was developed in part with a BARDA contract to detect COVID-19 and Influenza.
  • THE 5Ps, LLC (Major General Elder Granger)flagshipStrategic or Co-development PartnerStrategic Advisory Lead for Government and Military Medical Programs. General Granger (retired U.S. Army Major General) appointed April 2026 to lead RAIsonance's global strategic efforts with government and military programs, drawing on prior leadership of TRICARE (overseeing 9M+ beneficiaries) and the 44th Medical Command.
  • Christine Hrudka (Pharmacy Industry Strategic Advisory)flagshipGTM or Marketing PartnerStrategic Advisory Lead for the Pharmacy Industry appointed January 2026. Former Chair of Canadian Pharmacists Association; 20+ years operating Shoppers Drug Mart locations; will lead pharmacy programs across Canada, the United Kingdom, Australia and the US.
  • DRIVe (Division of Research, Innovation, and Ventures)coreStrategic or Co-development PartnerListed as partner on Our Partners page linking to drive.hhs.gov/digitalmcm.html, indicating engagement with HHS DRIVe (often a BARDA-adjacent innovation accelerator).
  • SotorcoreChannel Partner/ Reseller/ DistributorFeatured partner on RAIsonance's Our Partners page linking to sotertechnologies.com. Likely regional distribution or technology collaboration partner.
  • Biotech LatamcoreChannel Partner/ Reseller/ DistributorFeatured partner on Our Partners page linking to biometric.biotechlatam.solutions, suggesting Latin American distribution or biometric services collaboration.
  • Health Express 365coreChannel Partner/ Reseller/ DistributorFeatured partner on Our Partners page linking to healthexpress365.com, likely a healthcare distribution or screening services partner.
  • Well BeforecoreChannel Partner/ Reseller/ DistributorFeatured partner on Our Partners page linking to wellbefore.com, likely a consumer/retail health products distribution partner.
  • AbundaboxminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • AequusminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • BibeatminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • DawapayminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • HippominorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • KompsysminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • MaatminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • NIHTBminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • SalessquadminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • ZachminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.
  • ZendawaminorChannel Partner/ Reseller/ DistributorListed on Our Partners page; logo only without linked URL, indicating a smaller emerging-market distribution relationship.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Raisonance competitors and assessment

Company assessment

Direct peers

  • ResApp Health: Australian digital health company (acquired by Pfizer in 2022) that developed machine-learning analysis of cough sounds to diagnose respiratory diseases including pneumonia, asthma, and COPD. Closest direct peer to RAIsonance's AudibleHealth AI cough-based clinical decision support product.
  • Hyfe AI: AI cough-monitoring platform that analyzes cough frequency and patterns via smartphone microphones for respiratory disease tracking. Closely comparable to RAIsonance's FCV Sentinel use case of continuous cough-based monitoring, with a more research/consumer-research orientation.
  • Sonde Health: Voice biomarker platform using vocal audio analysis (including cough) for health monitoring and mental/physical condition detection. Directly comparable to RAIsonance's audio-based biomarker approach, though Sonde has emphasized mental health and cognitive conditions rather than respiratory screening.
  • Eko Health: Digital stethoscope plus AI platform that analyzes lung and heart sounds for respiratory and cardiac conditions, including FDA-cleared AI for detecting pulmonary conditions. Comparable AI-audio respiratory diagnostics competitor, though Eko uses a dedicated stethoscope rather than a generic smartphone.
  • NuvoAir: Digital respiratory health platform combining remote spirometry, symptom tracking, and AI for asthma/COPD management. Comparable to RAIsonance's respiratory disease screening and monitoring product set, with overlapping enterprise payer/provider business models.

Emerging players

  • Kintsugi: Voice biomarker startup using short voice clips to detect depression and other mental/physical health conditions. Comparable as an emerging audio-biomarker health AI company with a different clinical focus (mental health) than RAIsonance's respiratory focus.

Others

  • Cepheid (Danaher): Maker of GeneXpert molecular diagnostic systems (the confirmatory TB/COVID testing RAIsonance flags patients for). Indirectly tied to RAIsonance as the downstream confirmatory testing modality; not a competitor but the established incumbent whose installed base RAIsonance's screening complements rather than displaces.
  • Health Catalyst: Healthcare data and analytics platform serving hospitals and health systems. Indirect adjacency: Health Catalyst sits in the hospital IT/analytics stack where RAIsonance's screening outputs would integrate, rather than directly competing in respiratory diagnostics.

Broad incumbents

  • Babylon Health: AI-powered digital health and triage company offering symptom assessment and virtual care across multiple disease areas. Broad incumbent in AI health screening; competes for the same enterprise/payer budgets that fund AI-driven respiratory screening pilots.
  • Biofourmis: AI-based remote patient monitoring and digital therapeutics platform focused on chronic conditions including respiratory. Comparable as a broader AI health monitoring incumbent, especially relevant to RAIsonance's FCV Sentinel enterprise monitoring use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Raisonance social profiles

Digital presence

Raisonance compliance and trust

Trust signal

Compliance2 records

Raisonance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Raisonance leadership team

Management profile

Number of profiles

Profiles19 records

Raisonance funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Raisonance M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Raisonance

What does Raisonance do?

Raisonance develops AI/ML-based cough analysis software that screens for respiratory diseases (Tuberculosis, COVID-19, Pneumonia, Influenza) and provides biometric early-warning monitoring via a smartphone-based platform. Its core product AudibleHealth AI is a clinical decision support tool that analyzes a 10-second cough recording against 5,000+ data points, delivering results in approximately 30 seconds on Microsoft Azure cloud infrastructure, with FDA Emergency Use Authorization and ISO 13485 certification.

Is Raisonance a public or private company?

Raisonance is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Raisonance founded?

Raisonance was founded in 2020. It employs 11 to 50 people.

Where is Raisonance based?

Raisonance is headquartered in Denver, United States, in the North America region.

How does Raisonance make money?

Four revenue lines are on record. Enterprise / Institutional Software Licensing (AudibleHealth AI) is the primary driver. The others are subscription / SaaS (FCV Sentinel), government / Defense Contracts (BARDA) and exempt Securities Offering / Equity Financing.

Who are Raisonance's main competitors?

Direct peers on record are ResApp Health, Hyfe AI, Sonde Health, Eko Health and NuvoAir. Kintsugi is listed as an emerging player. Others are Cepheid (Danaher) and Health Catalyst. Broad incumbents are Babylon Health and Biofourmis.

Does Raisonance have an API?

No public API is recorded for Raisonance.

What industry is Raisonance in?

Raisonance's product category is AI Clinical Decision Support Software. Its primary akta.pro industry code is HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software, with a secondary code of HLACANAE, SaMD – Monitoring, Triage & Risk Stratification Software. Its NAICS code is 621511 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRAIsonance Releases New Fall 2023 Workforce Risk ForecastRAIsonance released its Fall 2023 Workforce Wellness Risk Forecast Report on August 22, 2023, providing employers with a science-based forecast of rising health risks expected to affect workforce health and productivity through the remainder of 2023. The report highlights that absenteeism alone costs U.S. companies an estimated $225.8 billion annually, with presenteeism adding up to $150 billion per year in lost productivity. Key findings include predictions of a new COVID-19 wave driven by the EG.5.1 Omicron sub-lineage peaking in early-to-mid September across the US, Canada, and UK, as well as concerns about the BA.2.86 sub-lineage detected in multiple countries.PR NewswireRAIsonance, Inc. Announces BARDA Contract to Continue Development of the AudibleHealth Dx Diagnostic SaMD for COVID-19 and Influenza Through AI-Powered Cough AnalysisRAIsonance, Inc. was awarded a BARDA contract to continue developing its AudibleHealth Dx diagnostic SaMD for COVID-19 and influenza. The contract, worth just over $749,000, aims to complete clinical validation and a de novo FDA submission by end of 2023. The device analyzes forced cough vocalizations via a mobile app, delivering results in about two minutes.PR NewswireRAIsonance Submits EUA Application to FDA for AudibleHealth DxRAIsonance submitted an FDA EUA application for its AudibleHealth Dx COVID-19 diagnostic software, which analyzes forced cough vocalization. The clinical validation study of 515 participants showed a positive percent agreement of 84.39% and negative percent agreement of 85.09% versus RT-PCR. The company plans to bring the test to market if authorized.PR NewswireRAIsonance, Inc. Joins Microsoft for Startups ProgramRAIsonance, Inc. has joined the Microsoft for Startups program, gaining access to Azure technologies and a path to sell alongside Microsoft's global partner ecosystem. The company utilizes AI-based solutions like SoundPass to address health and safety challenges through biometric signal data recognition.PR NewswireRAIsonance, Inc. Announces First Medical Advisory BoardRAIsonance, Inc., an AI-powered technology company headquartered in the Denver Tech Center focused on health and safety solutions, has established its first Medical Advisory Board with a two-year term starting June 2021. The board comprises distinguished medical professionals including cardiologists, emergency medicine specialists, and neuropsychologists from institutions such as Orlando Health, NYC Health & Hospitals, and University of South Florida. Founded in 2020 and partially funded by the National Science Foundation, the company stated that the advisory board will provide guidance to help bring its AI/ML technologies to market for healthcare diagnostics and safety applications.